ABSTRACT 47
INTRODUCTION 93
Pulmonary arterial hypertension (PAH) refers to a group of diseases with severe 94 pulmonary hypertension and concentric laminar and plexiform occlusive lesions of the 95 small pulmonary arteries and arterioles, i.e., plexogenic arteriopathy (45). If left 96 untreated, PAH follows a progressive, refractory, and fatal course, due to the 97 development of right ventricular (RV) failure (34). The persistently high mortality rates in 98 treated patients highlight the inadequacy of the current treatments of PAH (32). There is 99 now a general agreement that the complex pathology of PAH reflects its multifactorial 100 nature, which means several signaling pathways are aberrant in the process (9). This 101 accounts for the recent propensity towards using combination therapies for PAH (33) . 102
In addition, a recent report suggests that RV dysfunction in PAH might not be solely 103 attributable to the pressure overload caused by increased pulmonary vascular 104 resistance (6). Therefore, an ideal therapeutic strategy for PAH should be directed 105 simultaneously against the multiple dysregulated signaling pathways in both pulmonary 106 hypertension and RV dysfunction. 107
Dehydroepiandrosterone (DHEA) is a naturally occurring, cholesterol-derived steroid 108 hormone, secreted mainly from the adrenal cortex, and serves in humans as a 109 precursor for both estrogens and androgens (27) . DHEA has been solidly linked to a 110 wide variety of beneficial biological and physiological actions (53) . Recent reports have 111
shown that chronic DHEA treatment ameliorates experimental pulmonary hypertension 112 in rats and mice via multiple mechanisms, including vasodilatation (30) and anti-113 proliferative effects (31). However, the animal models utilized in these studies 114
[chronically hypoxic (7, 21, 38 ) and monocrotaline-injected rats (23, 40)] do not show 115 at 518/605 nm, using a Nikon Eclipse TE2000-U microscope. Data were analyzed 184 using Metamorph 7.1.2.0 software (Molecular Devices, Inc.). 185
Lucigenin chemiluminescence assay 186
Whole RV homogenates (20 μL) were added to microplate wells containing 5-μM 187 lucigenin for the detection of superoxide, as previously reported (51). Lucigenin as a percentage of the average thickness of the medial wall to the total outer diameter 216 of the vessel in at least 50 random, but consecutive, vessels per slide. 217
Histological studies 218
Formalin-fixed and paraffin-embedded heart tissue was stained with Masson's trichrome 219 stain to assess the degree of fibrosis (collagen fibers stain blue) within the heart tissue, 220 or left unstained for immunohistochemistry. Images were acquired using a Nikon E600 221 light microscope with digital interface and computer imaging software. 222
Immunohistochemical staining of paraffin-embedded slides was performed using 223
Vectastain Universal Quick Kit (Vector Laboratories), according to manufacturer's 224 recommendations. Briefly, slides were heated at 60°C, then sequentially washed in 225 xylene and gradual dilutions of ethanol for de-paraffenization. Antigen retrieval was 226 achieved by incubating the slides in heated (100°C) citrate buffer (1X, pH = 6, Dako). 227
Endogenous peroxidase activity was then suppressed by 3% hydrogen peroxide 228 treatment. Slides were incubated with a blocking buffer (1% universal horse serum) foran hour at room temperature, and then with the primary antibody under-study 230 overnight at 4°C. Incubations with a biotinylated universal secondary antibody (Dako) 231 and then avidin-biotin complex (Dako), each for 30 minutes at room temperature, then 232 followed. Detection of positive staining was done using 3,3'-Diaminobenzidine (DAB) 233 substrate chromogen system (Dako), and tissues were then counter-stained with 234 hematoxylin, and finally washed with xylene and ethanol. Primary antibodies used were 235 against: nitrotyrosine (Millipore), cleaved caspase 3 (Cell Signaling), and CD31 (Abcam 236
Inc.). Capillary density was expressed as CD31-positive spots per RV cross-sectional 237 area. Cardiomyocyte cross-sectional area was measured in at least 200 transversally 238 cut cardiomyocytes per each H&E-stained sample. TUNEL assay (ROCHE) was used 239 to detect apoptosis in the heart tissue. 240
Western blotting 241
Snap-frozen whole RV tissue was homogenized, and protein concentration in the 242 supernatant was determined using the BCA protein assay (Thermo Scientific), as 243 previously described (49). Standard methods of Western blotting were used to evaluate 244 the expression levels of collagen 1 (Santa Cruz), cleaved caspase 3 (Santa Cruz), Rho 245 kinase I/β (BD Pharmingen), Rho kinase II/α (BD Pharmingen), MYPT-1 (Millipore), P-246
Cruz), and β-actin (Santa Cruz). 248
Statistical analyses 249
Values shown are means ± SEM. Analysis of Variance (ANOVA) with Bonferroni post 250 hoc test was used for comparisons among the experimental groups. For correlations, 251 Abdallah Alzoubi et. al.
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Pearson calculations with two-tailed p value were first done and a linear regression 252 analysis was then used to create a best-fit line. Differences were considered significant 253 at P<0.05. 
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RESULTS
276
DHEA has more profound effects on cardiac output than on pulmonary arterial 277 pressure 278
Consistent with previous studies (1), SU/Hx/Nx rats showed marked increases in RV 279 systolic pressure (RVSP, Figure 2A ), total pulmonary resistance index (TPRI, Figure  280 2C), and the RV hypertrophy index: RV/LV+S weight ratio ( Figure 2D ), and a significant 281 attenuation of cardiac index (CI, Figure 2B ). Chronic DHEA treatment restored the 282 normal levels of CI, while only moderately reducing RVSP. The beneficial effects of 283 DHEA on cardiac output were derived from an improving right, rather than left, 284 ventricular function, as systolic systemic arterial pressure ( Figure 2E ) and heart rate 285 ( Figure 2F ) were not significantly different among the three groups. Furthermore, DHEA 286 treatment regressed pulmonary vascular remodeling, as it reduced both the medial wall 287 thickening of medium-sized pulmonary arteries ( Figure 2G) , and, to an even greater 288 extent, the luminal occlusion of small pulmonary arteries ( Figure 2H ). 289
DHEA reverses PAH-induced RV dysfunction 290
We utilized non-invasive echocardiography to more directly address the question of the SU/Hx/Nx group, corresponds to a more severe RV dysfunction, contrary to the late-306 systolic notching found in the DHEA-treated rats. 307
DHEA protects the RV against structural maladaptive remodeling 308
To evaluate the effects of DHEA treatment on RV structure, we performed a 309 morphometric analysis of RV fibrosis, cardiomyocyte cross-sectional area, and capillary 310 density in the 3 groups of rats. The RV of SU/Hx/Nx rats developed a high degree of 311 1-A expression levels in the RV. Importantly, left ventricles from the three experimental 315 groups had minimal fibrotic areas (data not shown), indicating that the left ventricle was 316 spared from the pulmonary hypertensive effects of SU/Hx/Nx, at least at the 8-week 317 time point. Moreover, the steroid treatment significantly reduced RV cardiomyocyte 318 cross-sectional area that was otherwise enlarged in SU/Hx/Nx rats ( Figures 4B and 4E) . 319
Additionally, and consistent with previous reports (6), chronic SU/Hx/Nx exposureresulted in the loss (rarefaction) of RV capillaries ( Figures 4C and 4F ). In contrast, 321 DHEA treatment recovered the normal density of RV capillaries. 322
Because cardiac fibrosis is frequently coupled to cardiomyocyte death, we also 323 examined the degree of RV apoptosis. RV from the SU/Hx/Nx group exhibited a 324 significant increase in apoptosis rates, as evaluated by the TUNEL assay (Figures 5A  325 and 5B), and active (cleaved) caspase 3 expression by immunohistochemistry (Figure  326 5C), and western blotting ( Figure 5D ). Interestingly, most apoptosis was observed in 327 and around the coronary vessels, which might explain the observed capillary rarefaction 328 in Figure 4 . Chronic DHEA treatment prevented RV apoptosis. 329
The anti-oxidant activity of DHEA plays a central role in its beneficial effects on 330
RV structure and function 331
Since chronic pressure overload alone is not sufficient to induce RV fibrosis and 332 apoptosis (6), it was important to explore other factors implicated in RV decompensation 333 and maladaptive remodeling, such as RV oxidative stress. There was a substantial 334 increase in DHE immunofluorescence in the RV of SU/Hx/Nx rats ( Figure 6A ), indicating 335 a marked increase in superoxide levels, which was completely blocked by DHEA 336 treatment. We also evaluated the formation of nitrotyrosine in the RV, as it has been 337 shown to be detrimental to cardiac structure and function by decreasing the 338 bioavailability of nitric oxide, which in turn results in coronary vasoconstriction (25). As 339 can be seen in Figure 6B , nitrotyrosine signal intensity was increased in the RV of 340 SU/Hx/Nx rats, most remarkably in the medial layer of coronary arteries. This was 341 significantly attenuated by chronic DHEA treatment. To quantify these results, we used 342 the lucigenin chemiluminescence assay ( Figure 6C ). Consistent with previous reportsshowing a basal level of reactive oxygen species (ROS) production in normal heart 344 tissue (28), the RV of untreated rats exhibited a baseline level of superoxide generation. 345
Chemiluminescence was significantly increased in the RV of SU/Hx/Nx rats. In contrast, 346 superoxide production was markedly reduced in the RV of DHEA-treated rats, and even 347 fell below baseline. Since NADPH oxidase is the main source of ROS in the heart (26), 348
we repeated the measurements after adding NADPH, which is the preferred substrate To further investigate the molecular mechanisms by which DHEA protects RV structure 360 and function in the context of PAH, we studied its effects on the Rho kinase (ROCK) 361 signaling pathway, because it is well-documented that ROCK is hyperactivated in 362 various cardiovascular diseases (11), and is involved in cardiac maladaptive structural 363 remodeling (29). As can be seen in Figure 7 , DHEA treatment inhibited the expression 364 levels and activity (phosphorylation of MYPT1) of ROCKI and ROCKII ( Figures 7A-C) , 365 all of which were upregulated in the RV of SU/Hx/Nx rats. The inhibition of ROCKactivity was accompanied by reductions in the active dephosphorylated form of the 367 nuclear factor of activated T-cells-cytoplasmic 3 (NFATc3, Figures 7D) We showed here that during 8 weeks of SU5416/hypoxia/normoxia exposure, rats 390 developed very severe occlusive pulmonary hypertension. A 5-week DHEA treatment 391 (from week 3 to week 8 after SU5416 injection) significantly reduced RVSP as 392 compared to the DHEA-untreated rats, although it was still much higher than that of 393 normal rats. In contrast, DHEA restored cardiac index to normal levels, leading to a 394 dramatic improvement of estimated total pulmonary resistance. The effect of DHEA on 395 cardiac index is likely restoration rather than prevention/maintenance, because we have 396 previously found that cardiac index in this model is already significantly impaired at the Because the beneficial effect of DHEA on cardiac index was more profound than that on 408 RVSP, and because a recent report suggests that certain factors other than pressure 409 overload may be implicated in the progression into RV dysfunction in this rat model of 410 PAH (6), we further examined cardiac function and structure. Functionally, DHEAimproved the main echocardiographic signs of progressive RV dysfunction. TAPSE 412 was of particular importance, because recent studies have confirmed its excellent 413 predictive value for RV ejection fraction and systolic function (16), which we validated 414 through the significant correlation between TAPSE and cardiac index. DHEA recovered 415 the control levels of TAPSE, indicating a preservation of the contractile functional 416 capacity of RV, which in turn explains the regression of signs of RV dilatation and 417 impending failure in these animals. 418
Structurally, DHEA prevented the terminal features of maladaptive RV remodeling, i.e., 419 RV capillary rarefaction, apoptosis and fibrosis. It is hypothesized that in the early 420 stages of PAH, the high pulmonary arterial pressure and pulmonary vascular resistance 421 and stiffness are compensated by an adaptive "concentric" RV hypertrophy (22) to 422 maintain normal levels of cardiac output. During the latter stages of the disease, 423 however, the continued pressure overload, in concert with other RV-damaging factors, 424 result in inhibition of angiogenesis and vascular cell apoptosis and rarefaction, which 425 ultimately lead to reduction in number of cardiomyocytes (6). Given the low rates of 426 cardiac cell regeneration (3), fibrosis is considered the main repair process in the heart. 427
The resulting "eccentric" remodeling, where parts of the RV are dilated and others are 428 hypertrophied, is a sign of impending RV failure. DHEA treatment recovered the normal 429 density of coronary capillaries, and inhibited both RV apoptosis and fibrosis, but in 430 contrast, it only moderately reduced the degree of RV hypertrophy. We, therefore, 431
propose that DHEA shifts the RV from the stage of partially compensated eccentric 432 remodeling seen in SU/Hx/Nx rats, into a fully compensated concentric RV hypertrophy 433 phenotype. (19) have reported that glucose-6-phosphate dehydrogenase (G6PD)-derived NADPH 451 is the principal fuel for the production of superoxide by NADPH oxidase in the failing left 452 heart. DHEA is documented to be a potent inhibitor of G6PD (20), and it thus regulates 453 the redox state of the cell by reducing the availability of NADPH. Collectively, our 454 current findings indicate that DHEA treatment suppressed NADPH production, and 455 consequently inhibited oxidative stress, in the RV of PAH rats.
Mechanistically, we found that DHEA inhibited the expression and activity of ROCK in 457 the RV. There is substantial evidence that the ROCK signaling pathway is activated in 458 various cardiovascular diseases, among which are PAH (35) and heart failure (10). We 459 have previously shown that DHEA treatment of left-pneumonectomized /monocrotaline-460 injected rats inhibited activation of lung RhoA/Rho kinase signaling, arrested 461 progression of PAH, increased cardiac output, and strikingly increased survival of the 462 rats (23). Moreover, Takeshima DHEA into estrogens and androgens could also contribute to the observed 475 cardioprotection in pulmonary hypertensive rats. However, the potential beneficial 476 effects of sex hormones, particularly estrogen, on PAH are still controversial. 477
The dose of DHEA used in this study is very high. However, effective doses in humans 478 might be much lower because of their very high basal DHEA levels compared to those 479 in rodents. DHEA has not been tested as a therapeutic option in human PAH, and 480 optimal dosing is therefore not known. However, a recent preliminary report of an 481 ongoing clinical trial in chronic obstructive lung disease-associated pulmonary 482 hypertension patients revealed that chronic DHEA treatment (200 mg/day for 12 weeks) 483 improved their exercise tolerance and hemodynamic parameters (12). 484
Although our results support the hypothesis that DHEA exerts a direct beneficial effect 485 on RV structure and function, independent of the decrease in pressure overload, we will 486 need to address this issue more definitively in our future work. For example, it may be 487 helpful to use the exclusive RV pressure-overload animal model, i.e., the pulmonary 488 artery-banding model, although this model provides variable results on RV dysfunction 489 and its mechanisms, depending on the severity and duration of banding (13, 14) . The results of this project provide a foundation for an effective and safe oral therapeutic 504 approach for severe PAH. Our findings suggest that DHEA has anti-pulmonary 505 hypertensive, as well as, potent direct RV protective effects, both structurally and 506 functionally. Besides being novel, these findings are highly significant, given the fact 507 that RV failure is the main cause of morbidity and mortality in PAH patients, and that 508 current treatments are expensive and minimally effective. 
